The Washington Post

Anxious and Depressed as a Scary Disease Destroyed Her Lungs, She Turned to MDMA for Relief. by Sarah Hogate Bacon • November 18, 2019

The Washington Post explores the benefits and risks of MDMA-assisted psychotherapy through the lens of the author, Sarah Hogate Bacon, who undertook various alternative treatment methods for anxiety and depression symptoms associated with her life-threatening illness, including MDMA-assisted psychotherapy. The article highlights published data from completed clinical trials of MDMA-assisted psychotherapy for PTSD, an update on ongoing FDA-regulated Phase 3 clinical trials, and a brief interview with study participant Ed Thompson. "Like any therapy, MDMA-guided psychotherapy is a process, not a quick fix," explains Sarah Hogate Bacon of The Washington Post.

FORTUNE

Business Gets Ready to Trip: How Psychedelic Drugs May Revolutionize Mental Health Care by Jeffrey M. O’Brien • February 17, 2020

"Across science, culture, politics, and business, a diverse community of supporters is forming to push psychedelics out of the shadows and into the mainstream," explains Fortune in an in-depth report on the expanding psychedelic renaissance. The article encompasses a spectrum of topics ranging from the growing support from influential donors such as author Tim Ferriss to the role MAPS has played in shifting public opinion about psychedelics through clinical research. "MAPS has played a key role in lowering cultural resistance to psychedelics over the past three decades, and it continues to bang the drum."

The New York Times

Taking Ayahuasca When You’re a Senior Citizen by Casey Schwartz • Oct. 17, 2019

Scientific data on older people using ayahuasca is elusive but anecdotal evidence is growing," explains The New York Times in a piece that features insights from senior citizens who participate in ayahuasca ceremonies. The article highlights prominent voices in the psychedelic community contributing to the conversation about age and psychedelics, including MAPS Founder Rick Doblin, Ph.D., who notes that older age groups can become more sensitive to psychoactive substances.

Forbes

Enthusiastic Donors Pony Up In Support Of Psychedelic Research, Harm Reduction Efforts by David Carpenter • Nov. 18, 2019

Forbes reports on growing donor support for psychedelic research and harm reduction efforts, including the Zendo Project’s psychedelic peer support services. The article attributes compelling results from clinical research conducted by MAPS and other esteemed organizations to the growing shift in public acceptance towards psychedelics, which may coincide with the expanding donor support for psychedelic research, harm reduction, and education.

KQED

Psychedelic Therapy Available to More People During Clinical Trials by Lauren Klivans on February 10, 2020

KQED speaks with MAPS Founder Rick Doblin, Ph.D., and Army SGT (R) Jon Lubecky about the Food and Drug Administration’s recent decision to grant Expanded Access to MDMA-assisted psychotherapy for PTSD. "The FDA is recognizing that there’s a humanitarian crisis with many, many millions of people that have treatment-resistant PTSD," explains Doblin.

CNN

Can the Mind-Blowing Effects of Psychedelics Help Heal Our Traumas? by Sandee LaMotte on January 27, 2020

"Today there is a true renaissance of research on the role of psychedelics on mental health," explains CNN as it explores the history and expansion of psychedelic research, highlighting MAPS-sponsored trials for both MDMA-assisted and LSD-assisted psychotherapy. The article also explores the growing shift in acceptance of psychedelic medicine in mainstream culture.